BBHVanEck Biotech ETF

Grow my money14y track recordRanked #996 of 2,960 in this goal

Seeks to replicate the price and yield performance of the MVIS US Listed Biotech 25 Index.

By VanEck · Launched 2011

Annual Cost

0.35%

#1,706 of 5,562 · low cost

Fund Size

$367M

#1,813 of 5,562 · large

Return (1Y)Goal

+24.3%

Track Record

14 years

#951 of 5,562 · established

Performance

Total-return NAV · USD

Growth of $10,000

$13,359+33.6%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

North america

Cap

Mid

Strategy

Index tracking

Sector

Health care

Focus

Biotech & Genomics

Index tracked

MVIS US Listed Biotech 25 Index

What it actually holds

By weight

Concentration

Top 10 holdings = 71.6% of fundconcentrated

Amgen Inc

15.1%

Gilead Sciences Inc

14.4%

Vertex Pharmaceuticals Inc

9.1%

Regeneron Pharmaceuticals Inc

7.7%

Argenx SE

4.7%

IQVIA Holdings Inc

4.5%

Alnylam Pharmaceuticals Inc

4.4%

Natera Inc

4.3%

Insmed Inc

4.1%

BeOne Medicines Ltd

3.2%

Asset allocation

Stocks

100.0%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

19.3%Moderate

Year-on-year price swings

Max drawdown

-39.9%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.21Below average

Sortino (3Y)

0.30Moderate downside risk

Where to buy

Listing

Exchange: NASDAQ Global Select Market

Full fund details

Objective: Seeks to replicate the price and yield performance of the MVIS US Listed Biotech 25 Index.
Strategy: Invests primarily in securities that comprise the Biotech Index, which includes U.S. exchange-listed companies in the biotechnology industry. The Fund uses a passive investment approach to replicate the Biotech Index's performance without seeking to outperform it.
Inception date: December 20, 2011
Fund family: VanEck